Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1981, current small-particle · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | - |
| Treatment B | EXPERIMENTAL | - |
| Treatment C | EXPERIMENTAL | - |
| Treatment D | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | AZD1981, 514 mg oral solution |
| 3 | EXPERIMENTAL | AZD1981, 500 mg oral tablet A |
| 4 | EXPERIMENTAL | AZD1981, 500 mg oral tablet B |
| Name | Type | Description |
|---|---|---|
| AZD1981, current small-particle tablet | DRUG | 3x100 mg per oral, single dose in fasted state |
| AZD1981, new small-particle tablet | DRUG | 3x100 mg per oral, single dose |
| AZD1981, new large-particle table | DRUG | 3x100 mg per oral, single dose in fasted state |
| AZD1981 | DRUG | Oral tablet, 250 mg, single dose |
| Placebo | DRUG | - |
Inclusion Criteria: * Healthy male and postmenopausal or surgically sterile female volunteers aged 18-55, inclusive * Have a body mass index between 19-30 kg/m2 and weigh at least 50 kg and no more than 100 kg, inclusive * Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to...
AZD1981 is an investigational small molecule being studied for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). It has also been evaluated in healthy volunteers for pharmacokinetic and drug interaction studies, including its effects on oral contraceptives and the QT interval.
AZD1981 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company has conducted clinical trials to assess the drug's efficacy and safety in patients with moderate to severe COPD.
AZD1981 is in Phase 2 clinical development for moderate to severe COPD. It has completed a Phase 2 efficacy and safety study, along with several Phase 1 trials in healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
AZD1981 has completed four clinical trials. The main efficacy study, NCT00690482, was a Phase 2 trial in patients with moderate to severe COPD. Other completed trials include NCT00859352, a Phase 1 study in healthy male volunteers, NCT01110525, a drug interaction study with oral contraceptives, and NCT01265641, a QT interval study.
AZD1981 is the code name for this investigational compound developed by AstraZeneca. No alternative brand names or other designations have been disclosed in the clinical trial records. The drug is identified solely by its development code AZD1981 in all completed studies.
AZD1981 is a small molecule being investigated for respiratory conditions. The specific molecular target or mechanism of action has not been disclosed in the available clinical trial information. The drug's efficacy in COPD was assessed in a placebo-controlled Phase 2 study, but its biological pathway remains unspecified.